StreetInsider.com News Articles

Form SCHEDULE 13D/A Outlook Therapeutics, Filed by: GMS Ventures & Investments

Mon, 01 Jun 2026 21:31:00 -0400

si-local-file:///var/storage/secattach/20260601/26585785.html

Form SCHEDULE 13D/A Outlook Therapeutics, Filed by: GMS Ventures & Investments

Mon, 01 Jun 2026 21:31:00 -0400

si-local-file:///var/storage/secattach/20260601/26585785.html

Form 4 Outlook Therapeutics, For: May 28 Filed by: Sukhtian Ghiath M.

Mon, 01 Jun 2026 21:30:00 -0400

si-local-file:///var/storage/secattach/20260601/26585780.html

Form 4 Outlook Therapeutics, For: May 28 Filed by: Sukhtian Ghiath M.

Mon, 01 Jun 2026 21:30:00 -0400

si-local-file:///var/storage/secattach/20260601/26585780.html

Form DEFA14A Outlook Therapeutics,

Mon, 01 Jun 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20260601/26584861.html

Form DEFA14A Outlook Therapeutics,

Mon, 01 Jun 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20260601/26584861.html

Form DEF 14A Outlook Therapeutics, For: Jul 16

Mon, 01 Jun 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260601/26584837.html

Form DEF 14A Outlook Therapeutics, For: Jul 16

Mon, 01 Jun 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260601/26584837.html

Form 8-K Outlook Therapeutics, For: Jun 01

Mon, 01 Jun 2026 09:15:00 -0400

si-local-file:///var/storage/secattach/20260601/26580503.html

Form 8-K Outlook Therapeutics, For: Jun 01

Mon, 01 Jun 2026 09:15:00 -0400

si-local-file:///var/storage/secattach/20260601/26580503.html

Outlook Therapeutics resubmits drug application to FDA after appeal win

Mon, 01 Jun 2026 08:47:09 -0400

Outlook Therapeutics Inc. (NASDAQ: OTLK) announced it has resubmitted its Biologics License Application to the U.S. Food and Drug Administration for ONS-5010/LYTENAVA™ (bevacizumab-vikg) to treat neovascular age-related macular degeneration.

The resubmission follows a successful appeal of a Complete Response Letter the FDA issued in December 2026. The FDA Office of New Drugs concluded that substantial evidence of effectiveness has been established for LYTENAVA™ and that additional trials are not required.

The FDA directed its Division of Ophthalmology and Office of Specialty Medicine to work with Outlook Therapeutics on final product labeling. The resubmission received a Class 1 review designation with a PDUFA

Outlook Therapeutics resubmits drug application to FDA after appeal win

Mon, 01 Jun 2026 08:47:09 -0400

Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)

Mon, 01 Jun 2026 08:46:00 -0400

ISELIN, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced the resubmission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ONS-5010/LYTENAVA™ for the treatment of neovascular age-related macular degeneration (nAMD).

As previously announced, Outlook Therapeutics successfully appealed the December 2026 Complete Response Letter (CRL) related to the ONS-5010 Biologics License Application reviewed by the FDA. In their decision, the FDA

Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)

Mon, 01 Jun 2026 08:46:00 -0400

Form 8-K Outlook Therapeutics, For: May 29

Fri, 29 May 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260529/26575773.html

Form 8-K Outlook Therapeutics, For: May 29

Fri, 29 May 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260529/26575773.html

Form 424B5 Outlook Therapeutics,

Fri, 29 May 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20260529/26571095.html

Form 424B5 Outlook Therapeutics,

Fri, 29 May 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20260529/26571095.html

Form 8-K Outlook Therapeutics, For: May 28

Thu, 28 May 2026 17:10:00 -0400

si-local-file:///var/storage/secattach/20260528/26568813.html

Form 8-K Outlook Therapeutics, For: May 28

Thu, 28 May 2026 17:10:00 -0400

si-local-file:///var/storage/secattach/20260528/26568813.html

Outlook Therapeutics prices $5 million stock offering at $0.59 per share

Thu, 28 May 2026 16:00:13 -0400

Outlook Therapeutics Inc. (NASDAQ: OTLK) announced it entered into an agreement to sell 8,539,709 shares of common stock at $0.5855 per share in a registered direct offering to GMS Ventures and Investments, its largest stockholder. The transaction is expected to generate $5 million in gross proceeds before deducting offering expenses.

The closing is expected to occur on or about May 29, 2026, subject to customary closing conditions. The company plans to use the net proceeds along with existing cash for working capital and general corporate purposes.

The offering is conducted under a shelf registration statement on Form S-3 that became effective with

Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Thu, 28 May 2026 16:00:00 -0400

ISELIN, N.J., May 28, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that it has entered into a definitive agreement providing for the purchase and sale of an aggregate of 8,539,709 shares of its common stock at a purchase price of $0.5855 per share in a registered direct offering priced at-the-market under Nasdaq rules to GMS Ventures and Investments, the Company’s largest stockholder. The closing of the offering is expected to

Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Thu, 28 May 2026 16:00:00 -0400

Form 4 Outlook Therapeutics, For: May 27 Filed by: Sukhtian Faisal Ghiath

Wed, 27 May 2026 15:29:00 -0400

si-local-file:///var/storage/secattach/20260527/26557364.html

Form 4 Outlook Therapeutics, For: May 27 Filed by: Sukhtian Faisal Ghiath

Wed, 27 May 2026 15:29:00 -0400

si-local-file:///var/storage/secattach/20260527/26557364.html